The PE Ratio as of December 2024 (TTM) for Madrigal Pharmaceuticals, Inc. (MDGL) is -12.41

According to Madrigal Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -12.41. This represents a change of 25.75% compared to the average of -9.87 of the last 4 quarters.

Madrigal Pharmaceuticals, Inc. (MDGL) Historical PE Ratio (quarterly & annually)

How has MDGL PE Ratio performed in the past?

The mean historical PE Ratio of Madrigal Pharmaceuticals, Inc. over the last ten years is -15.49. The current -12.41 PE Ratio has changed 7.91% with respect to the historical average. Over the past ten years (40 quarters), MDGL's PE Ratio was at its highest in in the March 2016 quarter at -0.06. The PE Ratio was at its lowest in in the June 2018 quarter at -155.69.

Madrigal Pharmaceuticals, Inc. (MDGL) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Madrigal Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Madrigal Pharmaceuticals, Inc. (MDGL) Average PE Ratio

How has MDGL PE Ratio performed in the past?

The current PE Ratio of Madrigal Pharmaceuticals, Inc. (MDGL) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages

Madrigal Pharmaceuticals, Inc. (MDGL) PE Ratio vs. Peers

How is MDGL’s PE Ratio compared to its peers?

Madrigal Pharmaceuticals, Inc.’s PE Ratio is greater than Intercept Pharmaceuticals, Inc. (-91.78), greater than TG Therapeutics, Inc. (-325.88), less than Terns Pharmaceuticals, Inc. (-5.24), less than Hepion Pharmaceuticals, Inc. (-0.15), greater than Viking Therapeutics, Inc. (-47.34), less than Sarepta Therapeutics, Inc. (94.46), less than PTC Therapeutics, Inc. (-7.73), greater than Day One Biopharmaceuticals, Inc. (-14.55), less than X4 Pharmaceuticals, Inc. (-6.92), less than Inozyme Pharma, Inc. (-1.97), less than Acumen Pharmaceuticals, Inc. (-1.30), less than Mereo BioPharma Group plc (-12.36), less than 89bio, Inc. (-2.96), less than Pliant Therapeutics, Inc. (-4.02), greater than Arcellx, Inc. (-102.24), less than Stoke Therapeutics, Inc. (-6.20), less than Krystal Biotech, Inc. (88.18), less than Iovance Biotherapeutics, Inc. (-5.52),

Build a custom stock screener for Madrigal Pharmaceuticals, Inc. (MDGL) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Madrigal Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Madrigal Pharmaceuticals, Inc. (MDGL) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Madrigal Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.